

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 2/6/07

Signature: Ginny Blundell

Docket No.: PROL-P01-041  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re Patent Application of:  
Alroy et al.

Application No.: 10/551,587

Confirmation No.: 2872

Filed: September 30, 2005

Art Unit: Not Yet Assigned

For: POSH POLYPEPTIDES, COMPLEXES AND  
RELATED METHODS

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98. The Examiner is respectfully requested to consider the listed documents and initial the enclosed Form PTO/SB/08 in the appropriate places to indicate that each document has been considered and to return a copy of the initialed form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. PROL-P01-041.

Dated: 2/6/07

Respectfully submitted,

By   
Anita Varma

Registration No.: 43,221  
FISH & NEAVE IP GROUP, ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-06)  
 Approved for use through 09/30/2006. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/551,587
				Filing Date	September 30, 2005
				First Named Inventor	Iris Alroy
				Art Unit	1635
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PROL-P01-041

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	5,283,317	02/01/1994	Saifer et al.	
	AB	6,455,263	09/24/2002	Payan	
	AC	6,737,244	05/18/2004	Issakani et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
	BA	WO03/078601		11/20/2003	Proteologics, Inc.		
	BB	WO03/095971		11/20/2003	Proteologics, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	ADACHI et al., 1986, Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone, J. Virol. 59:284-291	
	CB	BARTEL et al., 1993, Elimination of false positives that arise in using the two-hybrid system, Biotechniques 14:920-924	
	CC	FARAZI et al., 2001, The biology and enzymology of protein N-myristoylation, J. Biol. Chem. 276:39501-39504	
	CD	FUKOMORI et al., 2000, Regulation of cell cycle and apoptosis by human immunodeficiency virus type 1 Vpr, Microbes Infect. 2:1011-1017	
	CE	IWABUCHI et al., 1993, Use of the two-hybrid system to identify the domain of p53 involved in oligomerization, Oncogene 8:1693-1696	
	CF	IWATA et al., 2001, Subcellular compartment and molecular subdomain of beta-amyloid precursor protein relevant to the Abeta 42-promoting effects of Alzheimer mutant presenilin 2, J. Biol. Chem. 276:21678-21685	
	CG	KOKAME et al., 2000, Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress, J. Biol. Chem. 275:32846-32853	
	CH	LENARDO et al., 2002, Cytopathic killing of peripheral blood CD4(+) T lymphocytes by human immunodeficiency virus type 1 appears necrotic rather than apoptotic and does not require env, J. Virol. 76:5082-5093	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/551,587	
			Filing Date	September 30, 2005	
			First Named Inventor	Iris Alroy	
			Art Unit	1635	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	PROL-P01-041

	CI	LEVINE et al., 2002, Elevated homocysteine levels in young male patients with schizophrenia, Am. J. Psychiatry 159:1790-1792	
	CJ	MADURA et al., 1993, N-recognin/Ubc2 interactions in the N-end rule pathway, J. Biol. Chem. 268:12046-12054	
	CK	MARCHAND et al., 2002, Rapsyn escorts the nicotinic acetylcholine receptor along the exocytic pathway via association with lipid rafts, J. Neurosci. 22:8891-8901	
	CL	MATTSON and SHEA, 2003, Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders, Trends Neurosci. 26:137-146	
	CM	SAI et al., 2002, Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein, J. Biol. Chem. 277:12915-12920	
	CN	SANES and LICHTMAN, 1999, Development of the vertebrate neuromuscular junction, Ann. Rev. Neurosci. 22:389-442	
	CO	SCHNORR et al., 2001, Ras1 interacts with multiple new signaling and cytoskeletal loci in Drosophila eggshell patterning and morphogenesis, Genetics 159:609-622	
	CP	SCHUBERT et al., 1998, CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway, J. Virol. 72:2280-2288	
	CQ	TAPON et al., 1998, A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways, EMBO J. 17(5):1395-1404	
	CR	XU et al., 2003, POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis, EMBO J. 22:252-261	
	CS	ZERVOS et al., 1993, Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites, Cell 72:223-232	
	CT	ZHANG et al., 2001, Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine, Biochem. Biophys. Res. Comm. 289:718-724	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/551,587

Attorney Docket No.: PROL-P01-041

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on

2/6/07  
Date

Signature

Ginny Blundell

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant (25 References) (2 pages)  
References (22, BA-BB; CA-CT)